Idorsia

About Idorsia

Idorsia Ltd is a Swiss biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for unmet medical needs. Its clinical pipeline covers therapeutic areas such as central nervous system, cardiovascular, and immunological disorders, as well as orphan diseases. Key products include PIVLAZ for the prevention of cerebral vasospasm and QUVIVIQ for the treatment of insomnia. Idorsia also develops treatments for resistant hypertension, lupus, and Fabry disease, serving patients in Switzerland and internationally.